Anavex Life Sciences (AVXL) Competitors $9.44 -0.07 (-0.68%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL vs. MOR, SRRK, PTGX, CRNX, SWTX, OGN, CPRX, VKTX, XENE, and MLTXShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics Anavex Life Sciences (NASDAQ:AVXL) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk. Which has more volatility and risk, AVXL or MOR? Anavex Life Sciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Which has higher valuation and earnings, AVXL or MOR? Anavex Life Sciences has higher earnings, but lower revenue than MorphoSys. Anavex Life Sciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.55-17.15MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media refer more to AVXL or MOR? In the previous week, Anavex Life Sciences had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Anavex Life Sciences and 0 mentions for MorphoSys. Anavex Life Sciences' average media sentiment score of 1.19 beat MorphoSys' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Anavex Life Sciences Positive MorphoSys Neutral Does the MarketBeat Community prefer AVXL or MOR? Anavex Life Sciences received 417 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 74.92% of users gave Anavex Life Sciences an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformAnavex Life SciencesOutperform Votes44274.92% Underperform Votes14825.08% MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Do insiders & institutionals have more ownership in AVXL or MOR? 31.5% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is AVXL or MOR more profitable? Anavex Life Sciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Anavex Life Sciences' return on equity of -37.50% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -37.50% -34.08% MorphoSys -226.79%-694.31%-22.55% Do analysts rate AVXL or MOR? Anavex Life Sciences currently has a consensus target price of $44.00, indicating a potential upside of 366.35%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAnavex Life Sciences beats MorphoSys on 14 of the 18 factors compared between the two stocks. Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$802.58M$2.96B$5.51B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-17.1530.1522.5518.49Price / SalesN/A494.70394.97102.66Price / CashN/A168.6838.1834.62Price / Book6.643.166.694.25Net Income-$43M-$72.35M$3.22B$248.31M7 Day Performance-0.16%0.47%1.11%1.12%1 Month Performance17.64%7.67%3.59%3.68%1 Year Performance155.69%-22.98%15.65%5.19% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.8428 of 5 stars$9.44-0.7%$44.00+366.3%+160.3%$802.58MN/A-17.1540Upcoming EarningsNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0568 of 5 stars$29.81-3.1%$42.67+43.1%+124.3%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsGap DownPTGXProtagonist Therapeutics3.4698 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6563 of 5 stars$30.15-0.9%$73.00+142.1%-23.8%$2.81B$1.04M-8.08210Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.9424 of 5 stars$37.06-2.3%$73.20+97.5%-0.8%$2.78B$191.59M-10.65230Analyst ForecastNews CoverageOGNOrganon & Co.4.7614 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Positive NewsCPRXCatalyst Pharmaceuticals4.6728 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.4914 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Analyst ForecastOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.5924 of 5 stars$34.70-1.2%$56.78+63.6%-6.0%$2.66B$9.43M-12.30210Upcoming EarningsOptions VolumePositive NewsMLTXMoonLake Immunotherapeutics1.5529 of 5 stars$40.00+4.4%$80.50+101.3%+2.9%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies MOR Alternatives SRRK Alternatives PTGX Alternatives CRNX Alternatives SWTX Alternatives OGN Alternatives CPRX Alternatives VKTX Alternatives XENE Alternatives MLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVXL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVXL Stock Free AVXL Stock Alerts